HDL cholesterol — what your "good cholesterol" number really tells you

Q: Can I raise my HDL naturally?

Regular aerobic exercise, quitting smoking, and reducing insulin resistance (through diet, activity, and weight loss) can raise HDL modestly. But the goal is improving the underlying metabolic health those changes reflect — not the HDL number itself, which pharmacological trials showed isn't independently protective when forced up.

Q: My HDL is high — is that good or bad?

Moderately high HDL (60–80 mg/dL) is generally considered favorable. Very high HDL (well above ~80–100) has been linked to higher mortality in large cohorts, so an unusually high value is worth reviewing with your doctor alongside the rest of your labs rather than assuming it's protective.

Q: Why is my HDL low even though I'm healthy?

HDL has a genetic component and is also lowered by high triglycerides, insulin resistance, smoking, and some medications. A low HDL with otherwise excellent metabolic markers (low triglycerides, normal insulin, low ApoB) carries different weight than low HDL within a full insulin-resistance pattern.

Q: Does fasting matter for HDL?

HDL itself is fairly stable fed or fasted, but it's usually drawn as part of a lipid panel that includes triglycerides — and triglycerides do require a 9–12 hour fast for accurate interpretation. Follow the fasting instruction given for the panel.

Paired condition: High cholesterol lab work

Quick answer

HDL cholesterol ("good cholesterol") is inversely associated with cardiovascular risk — low HDL is a reliable *marker* of risk, especially as part of the insulin-resistance pattern. But it's not a lever you fix in isolation: trials that raised HDL pharmacologically didn't reduce events, and very high HDL is paradoxically associated with higher mortality. HDL is best read as a signal within the whole lipid and metabolic picture, not a target to maximize.

Reference ranges and interpretation

Value / population	Classification	What it means
< 40 mg/dL (men) / < 50 (women)	Low	Independent cardiovascular risk marker; common with insulin resistance.
40 – 59 mg/dL	Typical	Middle of the population range.
≥ 60 mg/dL	Favorable (historically)	Traditionally considered protective.
> 80 – 100 mg/dL	Very high — reassess	Extreme HDL is paradoxically associated with higher mortality in large cohorts.

Sex-specific cutoffs matter: the low-HDL threshold is < 40 mg/dL for men and < 50 mg/dL for women. HDL is one input to overall risk, not a standalone verdict.

Low HDL as a marker vs. a target

Decades of epidemiology show low HDL tracks with higher cardiovascular risk, and it's built into risk calculators for that reason. The catch: that's an association. When trials raised HDL directly — niacin added to statin therapy in AIM-HIGH, and extended-release niacin plus laropiprant in HPS2-THRIVE — cardiovascular events did not fall, and side effects rose. The lesson: low HDL is a useful warning light, but pushing the number up pharmacologically doesn't fix the underlying risk. Address the cause (usually insulin resistance and lifestyle) rather than the number.

The high-HDL surprise

"Higher is always better" turns out to be wrong at the extremes. In large Danish general-population cohorts, people with very high HDL (roughly > 100 mg/dL in men, > 135 in women) had higher all-cause mortality — a U-shaped relationship. The mechanism isn't fully understood, but it means an unusually high HDL is a reason to look at the whole picture with a clinician, not to celebrate.

What to read alongside HDL

HDL is most informative in context:

- Triglycerides — high triglycerides + low HDL is the classic insulin-resistance dyslipidemia
- Triglyceride / HDL ratio — a practical metabolic-risk surrogate; < 2.0 is favorable
- LDL-C and ApoB — the causal, treatable side of lipid risk (ApoB counts atherogenic particles)
- Lp(a) — an independent, largely genetic risk marker checked at least once
- Fasting insulin / HbA1c — the metabolic drivers behind a low HDL

A "normal" HDL alongside high triglycerides and high ApoB is not reassuring; the pattern matters more than any single value.

Phi Longevity reads every marker on every lab you upload — together, against your history, against optimal ranges, and across time. The integrated picture tells you what a single number can't.

Start with my labs →

Frequently asked questions

Can I raise my HDL naturally?

Regular aerobic exercise, quitting smoking, and reducing insulin resistance (through diet, activity, and weight loss) can raise HDL modestly. But the goal is improving the underlying metabolic health those changes reflect — not the HDL number itself, which pharmacological trials showed isn't independently protective when forced up.

My HDL is high — is that good or bad?

Moderately high HDL (60–80 mg/dL) is generally considered favorable. Very high HDL (well above ~80–100) has been linked to higher mortality in large cohorts, so an unusually high value is worth reviewing with your doctor alongside the rest of your labs rather than assuming it's protective.

Why is my HDL low even though I'm healthy?

HDL has a genetic component and is also lowered by high triglycerides, insulin resistance, smoking, and some medications. A low HDL with otherwise excellent metabolic markers (low triglycerides, normal insulin, low ApoB) carries different weight than low HDL within a full insulin-resistance pattern.

Does fasting matter for HDL?

HDL itself is fairly stable fed or fasted, but it's usually drawn as part of a lipid panel that includes triglycerides — and triglycerides do require a 9–12 hour fast for accurate interpretation. Follow the fasting instruction given for the panel.

References

All citations verified against PubMed / publisher of record (see note below for this page's verification date).

1.Grundy SM, Stone NJ, Bailey AL, et al. (2019). 2018 AHA/ACC/Multisociety Guideline on the Management of Blood Cholesterol. Circulation. 139(25):e1082-e1143. — US cholesterol guideline — HDL's role in risk assessment and why LDL/ApoB are the treatment targets.PubMed →DOI →
2.Madsen CM, Varbo A, Nordestgaard BG. (2017). Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. European Heart Journal. 38(32):2478-2486. — Source for the U-shaped HDL–mortality relationship at very high HDL.PubMed →DOI →
3.AIM-HIGH Investigators; Boden WE, Probstfield JL, et al. (2011). Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine. 365(24):2255-2267. — Raising HDL with niacin on top of statin did not reduce cardiovascular events.PubMed →DOI →
4.HPS2-THRIVE Collaborative Group. (2014). Effects of extended-release niacin with laropiprant in high-risk patients. New England Journal of Medicine. 371(3):203-212. — Confirms no event benefit from pharmacologically raising HDL; excess adverse effects.PubMed →DOI →

Reference ranges vary by lab and assay. This page is educational and not a substitute for individualized medical advice; lipid management should be guided by a clinician using your full risk profile.

By Steve Pinedo

Co-founder, Phi Longevity

Last updated: 2026-07-20

Steve Pinedo is the Co-founder of Phi Longevity, the AI application that turns a confusing stack of lab reports, wearable data, and clinical notes into a single, integrated picture of your health. He started Phi Longevity to make proactive health and wellness far easier to achieve. He realized how difficult it was for clients to manage their own care, records and coordination so he assembled a comprehensive M.D. led clinical team behind the platform, packaging the proactive-care experience that delivered measurable outcomes (lower triglycerides, reduced body fat, improved LDL, balanced hormones, relief from long-running autoimmune conditions) for any patient with a complicated lab to use now with an application. More about Phi Longevity →

High cholesterol labs

The full lipid pattern HDL lives inside.

Triglycerides

The other half of the trig/HDL metabolic signal.

ApoB

The atherogenic-particle count that refines lipid risk.